Wendy Young Buys Shares of Adial Pharmaceuticals

On June 12, 2026, Wendy Young purchased 36,378 shares of Adial Pharmaceuticals, Inc. (NasdaqCM: ADIL) at an average price of $2.75 per share. The transaction was valued at approximately $100,039.50 and was not part of a pre-arranged trading plan.

Insider Buying and Selling at Adial Pharmaceuticals, Inc.

Wendy Young's recent acquisition of shares wasn't the only insider activity at Adial Pharmaceuticals. On the same day, Chief Development Officer Matt Davidson also purchased shares, adding 232,417 shares to his portfolio. Earlier, on April 7, CEO Cary Claiborne acquired 37,985 shares.

Other Institutional Activity in Adial Pharmaceuticals

Several institutional investors have been adjusting their positions in Adial Pharmaceuticals. Geode Capital Management, LLC increased its holdings by 18,019 shares, now holding 24,249 shares valued at about $43,405. Vanguard Fiduciary Trust Co added 5,879 shares, totaling 5,879 shares worth $10,523. Meanwhile, Manchester Capital Management LLC slightly trimmed its stake by 1 share, ending with 1,923 shares valued at $3,443.

Adial Pharmaceuticals Stock Snapshot

Shares of Adial Pharmaceuticals, trading under the ticker ADIL on NasdaqCM, were last spotted at $2.85. The company has a market capitalization of roughly $6.24 million. It operates with a forward P/E ratio that is not meaningful due to its lack of profitability. The stock has seen a 52-week range between $1.31 and $19.00. Its 50-day moving average is $1.87, and the 200-day moving average stands at $5.16. Adial has a current ratio of 3.18 and a quick ratio of 3.04.

Analysts Set New Price Targets

On June 15, 2026, Lucid Capital Markets initiated coverage on Adial Pharmaceuticals with a 'buy' rating and set a price target of $6. Maxim Group had previously upgraded the stock to a 'buy' with a target of $1.50 on September 30, 2025. The consensus among analysts is a 'buy' rating, with a mean price target of $8, based on one analyst's opinion.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc. is a biotechnology company based in Glen Allen, Virginia. It focuses on developing treatments for addiction and related disorders. The company's lead product, AD04, is in Phase 3 trials for alcohol use disorder. Adial also works on drug candidates for non-opioid pain management and other conditions. The company was founded in 2010 and is led by CEO Cary John Claiborne.

Bottom Line

Wendy Young's purchase of Adial Pharmaceuticals shares signals confidence in the company's future. Investors keep an eye on insider trades as they can provide insights into company prospects. While Adial is still in the clinical trial phase, its stock has seen significant interest from both insiders and analysts, reflecting potential growth opportunities.